Elevating and De-Risking Your Drug Portfolio Strategy With AI

News
Article

Artificial intelligence (AI) can improve risk assessment and decision-making in drug development by applying objective, data-driven criteria consistently. Companies should focus on the quality of data, selecting the right AI use cases, and leveraging external partners to maximize the potential of AI.

Related Content